Cantor Fitzgerald Predicts DRUG FY2025 Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUGFree Report) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for Bright Minds Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the company will post earnings of ($0.62) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($2.58) per share.

Bright Minds Biosciences (NASDAQ:DRUGGet Free Report) last announced its quarterly earnings results on Monday, December 30th. The company reported ($0.12) earnings per share for the quarter.

Several other research firms have also commented on DRUG. Baird R W raised Bright Minds Biosciences to a “strong-buy” rating in a research report on Monday, November 25th. Robert W. Baird began coverage on shares of Bright Minds Biosciences in a research report on Monday, November 25th. They set an “outperform” rating and a $75.00 target price on the stock. Piper Sandler began coverage on shares of Bright Minds Biosciences in a research note on Thursday. They set an “overweight” rating and a $93.00 price target on the stock. Finally, HC Wainwright initiated coverage on shares of Bright Minds Biosciences in a research report on Friday, January 10th. They issued a “buy” rating and a $85.00 price objective for the company. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $84.33.

Check Out Our Latest Report on DRUG

Bright Minds Biosciences Price Performance

Shares of NASDAQ DRUG opened at $32.28 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.31 and a quick ratio of 11.31. Bright Minds Biosciences has a 1-year low of $0.93 and a 1-year high of $79.02. The company has a market capitalization of $143.13 million, a price-to-earnings ratio of -64.56 and a beta of -6.52. The business has a 50-day moving average of $38.36 and a 200-day moving average of $21.08.

Bright Minds Biosciences Company Profile

(Get Free Report)

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.

Featured Articles

Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.